InsightsPremium

Mark C. Genovese

Director at Kyverna Therapeutics

Mark C. Genovese, MD, is the SVP for Inflammation Clinical Research at Gilead Sciences. He oversees all clinical research endeavors in the areas of Rheumatology, Pulmonary, GI, Liver, Kidney, and Male Health at Gilead Sciences. He is the James W. Raitt Professor of Medicine-Emeritus and is the former Clinical Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center from 1998-2020. He received his bachelor’s degree from the University of Notre Dame and his medical degree from the Johns Hopkins University School of Medicine. He completed an internship, residency, and chief residency in the Department of Medicine at Stanford University. He remained at Stanford as a fellow in the Division of Immunology and Rheumatology and subsequently joined the faculty in the same division serving as the Clinical chief. Dr Genovese led a patient oriented clinical research program that was focused on translational medicine in autoimmune diseases. He designed and led numerous investigator-initiated studies and international multi-center trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. In addition, he collaborated with other investigators on studies of biomarkers and surrogates associated with disease progression and response to therapy in various autoimmune diseases and arthritis. Dr Genovese previously served as Director of the Center for Clinical Investigation at Stanford University. He is an author of over 200 peer review articles, editor on the 7th edition of Kelley’s Textbook of Rheumatology. He is the recipient of the 2008 American College of Rheumatology Henry Kunkel award, and is the Emeritus James W. Raitt Endowed Professor of Medicine at Stanford.

Roles

  • Director

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.